NCT05397431

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 155 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

Conditions

• Hereditary Angioedema (HAE)

Interventions

Type	Name	Description
DRUG	Lanadelumab	Lanadelumab 300 mg, subcutaneous injection every 2 weeks

Timeline

• Start date: 2022-05-30
• Primary completion: 2026-06-25
• Completion: 2026-06-25
• First posted: 2022-05-31
• Last updated: 2026-04-13

Locations

1 site across 1 country: Japan